.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Cerilliant
Dow
Deloitte
Mallinckrodt
Novartis
Julphar
Citi
AstraZeneca
Federal Trade Commission

Generated: September 25, 2017

DrugPatentWatch Database Preview

Idelalisib - Generic Drug Details

« Back to Dashboard

What are the generic sources for idelalisib and what is the scope of idelalisib patent protection?

Idelalisib
is the generic ingredient in one branded drug marketed by Gilead Sciences Inc and is included in one NDA. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Idelalisib has one hundred and twenty-nine patent family members in forty-five countries.

One supplier is listed for this compound.

Summary for Generic Name: idelalisib

Tradenames:1
Patents:12
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list59
Clinical Trials: see list49
Patent Applications: see list134
Drug Prices:see low prices
DailyMed Link:idelalisib at DailyMed

Pharmacology for Ingredient: idelalisib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead Sciences Inc
ZYDELIG
idelalisib
TABLET;ORAL205858-002Jul 23, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Gilead Sciences Inc
ZYDELIG
idelalisib
TABLET;ORAL205858-001Jul 23, 2014RXYesNo► Subscribe► SubscribeYY ► Subscribe
Gilead Sciences Inc
ZYDELIG
idelalisib
TABLET;ORAL205858-001Jul 23, 2014RXYesNo► Subscribe► SubscribeYY ► Subscribe
Gilead Sciences Inc
ZYDELIG
idelalisib
TABLET;ORAL205858-002Jul 23, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Gilead Sciences Inc
ZYDELIG
idelalisib
TABLET;ORAL205858-002Jul 23, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Gilead Sciences Inc
ZYDELIG
idelalisib
TABLET;ORAL205858-002Jul 23, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Gilead Sciences Inc
ZYDELIG
idelalisib
TABLET;ORAL205858-001Jul 23, 2014RXYesNo► Subscribe► SubscribeY ► Subscribe
Gilead Sciences Inc
ZYDELIG
idelalisib
TABLET;ORAL205858-002Jul 23, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Gilead Sciences Inc
ZYDELIG
idelalisib
TABLET;ORAL205858-001Jul 23, 2014RXYesNo► Subscribe► Subscribe► Subscribe
Gilead Sciences Inc
ZYDELIG
idelalisib
TABLET;ORAL205858-002Jul 23, 2014RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: idelalisib

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,779,1316-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta► Subscribe
6,518,277 Inhibitors of human phosphatidylinositol 3-kinase delta► Subscribe
8,653,077Inhibitors of human phosphatidylinositol 3-kinase delta► Subscribe
8,623,881Inhibitors of human phosphatidylinositol 3-kinase delta► Subscribe
9,487,772Inhibitors of human phosphatidylinositol 3-kinase delta► Subscribe
8,586,5976-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta► Subscribe
7,932,260Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta► Subscribe
8,207,153Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta► Subscribe
6,667,300 Inhibitors of human phosphatidylinositol 3-kinase delta► Subscribe
9,238,070Therapies for hematologic malignancies► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: idelalisib

Country Document Number Estimated Expiration
New Zealand522076► Subscribe
World Intellectual Property Organization (WIPO)0181346► Subscribe
Denmark2223922► Subscribe
Serbia55551► Subscribe
Costa Rica20140460► Subscribe
Eurasian Patent Organization008241► Subscribe
MexicoPA02010618► Subscribe
Japan4642309► Subscribe
New Zealand629684► Subscribe
Canada2406278► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: IDELALISIB

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0867Netherlands► SubscribePRODUCT NAME: IDELALISIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/14/938 20140919
2017004Lithuania► SubscribePRODUCT NAME: IDELALISIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/14/938 20140918
2017000008Germany► SubscribePRODUCT NAME: LDELALISIB ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/938 20140918
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
AstraZeneca
Daiichi Sankyo
Mallinckrodt
Queensland Health
Farmers Insurance
Novartis
Covington
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot